J. C. Vázquez Limón

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

M. Burotto, A. Armstrong, L. Lacombe, 2022, Journal for ImmunoTherapy of Cancer.

CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, M. Burotto, D. Shaffer, 2021 .

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.

F. Saad, A. Armstrong, D. Shaffer, 2021, European journal of cancer.

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.

R. Shapira-Frommer, G. Ke, S. Wildsmith, 2023, The Lancet. Oncology.